CA2801223C - Fusion protein having factor vii activity - Google Patents
Fusion protein having factor vii activity Download PDFInfo
- Publication number
- CA2801223C CA2801223C CA2801223A CA2801223A CA2801223C CA 2801223 C CA2801223 C CA 2801223C CA 2801223 A CA2801223 A CA 2801223A CA 2801223 A CA2801223 A CA 2801223A CA 2801223 C CA2801223 C CA 2801223C
- Authority
- CA
- Canada
- Prior art keywords
- fvii
- fusion protein
- linker
- seq
- transferrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2010-0052719 | 2010-06-04 | ||
| KR20100052719 | 2010-06-04 | ||
| PCT/KR2011/004131 WO2011152694A2 (en) | 2010-06-04 | 2011-06-07 | Fusion protein having factor vii activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2801223A1 CA2801223A1 (en) | 2011-12-08 |
| CA2801223C true CA2801223C (en) | 2019-12-03 |
Family
ID=45067214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2801223A Active CA2801223C (en) | 2010-06-04 | 2011-06-07 | Fusion protein having factor vii activity |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9644197B2 (https=) |
| EP (1) | EP2576625B1 (https=) |
| JP (2) | JP6143297B2 (https=) |
| KR (1) | KR101331101B1 (https=) |
| CN (2) | CN103068854A (https=) |
| AU (1) | AU2011262494B2 (https=) |
| BR (1) | BR112012030941A2 (https=) |
| CA (1) | CA2801223C (https=) |
| ES (1) | ES2676874T3 (https=) |
| MX (1) | MX348567B (https=) |
| RU (1) | RU2585231C2 (https=) |
| WO (1) | WO2011152694A2 (https=) |
| ZA (1) | ZA201300066B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2585231C2 (ru) | 2010-06-04 | 2016-05-27 | Ск Кемикалз Ко., Лтд. | Слитый белок, обладающий активностью фактора vii |
| ES2630031T3 (es) * | 2010-09-28 | 2017-08-17 | Aegerion Pharmaceuticals, Inc. | Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada |
| US20140056870A1 (en) * | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
| KR20140106448A (ko) | 2013-02-25 | 2014-09-03 | 에스케이케미칼주식회사 | 인자 vii을 포함하는 융합 단백질의 분리 및 정제 방법 |
| KR102058864B1 (ko) * | 2013-12-16 | 2019-12-24 | 주식회사 티움바이오 | 인자 vii의 융합 단백질을 포함하는 안정성이 개선된 약학적 조성물 |
| EP3351263A1 (en) | 2017-01-20 | 2018-07-25 | Universitätsklinikum Hamburg-Eppendorf | Pharmaceutical preparation for treating or preventing tissue adhesion |
| EP3668972B8 (en) | 2017-08-18 | 2024-11-13 | Neutrolis, Inc. | Engineered dnase enzymes and use in therapy |
| US10988746B2 (en) | 2018-10-08 | 2021-04-27 | Neutrolis, Inc. | Manufacturing and engineering of DNASE enzymes for therapy |
| AU2019358915B2 (en) | 2018-10-08 | 2025-09-18 | Neutrolis, Inc. | Engineering of DNASE enzymes for manufacturing and therapy |
| CN110218259B (zh) * | 2019-06-24 | 2022-09-16 | 王跃驹 | 植物生产胰高血糖素样肽-1短肽与转铁蛋白的融合蛋白制造口服降糖胶囊的应用 |
| CN110229237A (zh) * | 2019-06-24 | 2019-09-13 | 王跃驹 | 植物生产口服epo与转铁蛋白融合蛋白胶囊的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE60138364D1 (de) * | 2000-02-11 | 2009-05-28 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
| CN101177456A (zh) * | 2001-08-30 | 2008-05-14 | 比奥雷克西斯药物公司 | 经修饰的运铁蛋白融合蛋白 |
| US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
| US7176278B2 (en) * | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| RU2004109222A (ru) | 2001-08-30 | 2005-10-20 | Байорексис Фармасьютикал Корпорейшн (Us) | Слитые белки модифицированного трансферрина |
| US7125843B2 (en) * | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
| JP4567437B2 (ja) | 2002-05-01 | 2010-10-20 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 抗凝固剤としての新規組織因子標的化されたトロンボモジュリン融合タンパク質 |
| EP1545595B1 (en) * | 2002-08-30 | 2010-07-07 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains |
| US20070072271A1 (en) * | 2004-01-07 | 2007-03-29 | Novo Nordisk Healthcare A/G | Method for the production of recombinant proteins |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| EP2004683B1 (en) * | 2006-03-24 | 2016-05-11 | Biogen Hemophilia Inc. | Pc5 as a factor ix propeptide processing enzyme |
| GB0614780D0 (en) * | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| WO2009086132A2 (en) | 2007-12-20 | 2009-07-09 | University Of Southern California | Design of spacers to increase the expression of recombinant fusion proteins |
| EP3412300A1 (en) | 2008-06-27 | 2018-12-12 | Duke University | Therapeutic agents comprising elastin-like peptides |
| EP2509502A2 (en) * | 2009-12-08 | 2012-10-17 | Koninklijke Philips Electronics N.V. | A method and a correction system for correcting tracer-uptake measurements |
| RU2585231C2 (ru) | 2010-06-04 | 2016-05-27 | Ск Кемикалз Ко., Лтд. | Слитый белок, обладающий активностью фактора vii |
-
2011
- 2011-06-07 RU RU2012157301/10A patent/RU2585231C2/ru active
- 2011-06-07 US US13/701,333 patent/US9644197B2/en not_active Expired - Fee Related
- 2011-06-07 BR BR112012030941A patent/BR112012030941A2/pt not_active Application Discontinuation
- 2011-06-07 CN CN2011800277076A patent/CN103068854A/zh active Pending
- 2011-06-07 ES ES11790052.2T patent/ES2676874T3/es active Active
- 2011-06-07 AU AU2011262494A patent/AU2011262494B2/en active Active
- 2011-06-07 JP JP2013513120A patent/JP6143297B2/ja not_active Expired - Fee Related
- 2011-06-07 CN CN201710403215.1A patent/CN107188970A/zh active Pending
- 2011-06-07 WO PCT/KR2011/004131 patent/WO2011152694A2/en not_active Ceased
- 2011-06-07 EP EP11790052.2A patent/EP2576625B1/en active Active
- 2011-06-07 MX MX2012013807A patent/MX348567B/es active IP Right Grant
- 2011-06-07 KR KR1020110054573A patent/KR101331101B1/ko active Active
- 2011-06-07 CA CA2801223A patent/CA2801223C/en active Active
-
2013
- 2013-01-03 ZA ZA2013/00066A patent/ZA201300066B/en unknown
-
2016
- 2016-03-25 US US15/080,757 patent/US10696960B2/en active Active
- 2016-07-01 JP JP2016131637A patent/JP6422918B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2576625A4 (en) | 2013-11-06 |
| JP2017000144A (ja) | 2017-01-05 |
| EP2576625A2 (en) | 2013-04-10 |
| ES2676874T3 (es) | 2018-07-25 |
| MX348567B (es) | 2017-06-20 |
| KR20110133454A (ko) | 2011-12-12 |
| US20130236945A1 (en) | 2013-09-12 |
| US20160194622A1 (en) | 2016-07-07 |
| CN103068854A (zh) | 2013-04-24 |
| RU2585231C2 (ru) | 2016-05-27 |
| JP6143297B2 (ja) | 2017-06-07 |
| JP2013529914A (ja) | 2013-07-25 |
| CN107188970A (zh) | 2017-09-22 |
| AU2011262494A1 (en) | 2013-01-24 |
| CA2801223A1 (en) | 2011-12-08 |
| US10696960B2 (en) | 2020-06-30 |
| WO2011152694A8 (en) | 2013-01-17 |
| EP2576625B1 (en) | 2018-04-25 |
| ZA201300066B (en) | 2014-03-26 |
| MX2012013807A (es) | 2012-12-17 |
| BR112012030941A2 (pt) | 2017-06-06 |
| US9644197B2 (en) | 2017-05-09 |
| KR101331101B1 (ko) | 2013-11-19 |
| RU2012157301A (ru) | 2014-07-20 |
| WO2011152694A3 (en) | 2012-04-19 |
| AU2011262494A2 (en) | 2013-08-01 |
| JP6422918B2 (ja) | 2018-11-14 |
| AU2011262494B2 (en) | 2016-01-21 |
| WO2011152694A2 (en) | 2011-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2801223C (en) | Fusion protein having factor vii activity | |
| US8828939B2 (en) | Modified vitamin K dependent polypeptides | |
| KR101579083B1 (ko) | 연장된 반감기를 갖는 변형된 응고 인자 ＶＩＩａ | |
| SG186875A1 (en) | Chimeric clotting factors | |
| CA2981467C (en) | Fusion protein with factor ix activity | |
| US20220259287A1 (en) | Single chain factor viii molecule | |
| AU2020242945B2 (en) | Factor IX variants and uses thereof in therapy | |
| US20160060612A1 (en) | Method of Isolating and Purifying Fusion Protein Comprising Factor VII |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160510 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD Year of fee payment: 14 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250320 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250320 |